A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Trarbach, T
  • Major, Pierre
  • Lenz, HJ
  • Kerr, D
  • Pendergrass, K
  • Douillard, JY
  • Chen, B
  • Littlewood-Evans, A
  • Laurent, D
  • Jacques, C
  • Van Cutsem, E

publication date

  • January 1, 2006